Lincocin

Country: New Zealand

Bahasa: Inggeris

Sumber: Medsafe (Medicines Safety Authority)

Bahan aktif:

Lincomycin hydrochloride monohydrate 300 mg/mL;  

Boleh didapati daripada:

Pharmacia Limited Company trading as Pharmacia

INN (Nama Antarabangsa):

Lincomycin hydrochloride monohydrate 300 mg/mL

Dos:

300 mg/mL

Borang farmaseutikal:

Solution for injection

Komposisi:

Active: Lincomycin hydrochloride monohydrate 300 mg/mL   Excipient: Benzyl alcohol Water for injection

Unit dalam pakej:

Syringe, 2 mL

Kelas:

Prescription

Jenis preskripsi:

Prescription

Dikeluarkan oleh:

Pfizer Pharmaceuticals LLC

Ringkasan produk:

Package - Contents - Shelf Life: Syringe, - 2 mL - 60 months from date of manufacture stored at or below 25°C

Tarikh kebenaran:

1969-12-31

Ciri produk

 
Version: pfdlinci11210 
MoH Approved: 

Commercial/Non-Commercial 
Page 1 of 9 
DATA SHEET 

LINCOCIN
®

LINCOMYCIN INJECTION 
DESCRIPTION 
Non-proprietary name:  lincomycin hydrochloride 
Chemical Name: Lincomycin hydrochloride consists mainly of the
monohydrate of methyl 
6,8-dideoxy-6-[(_2S,4R_)-1-methyl-4-propylpyrrolidine-2-carboxamido]-1-thio-
D
-erythro-
-
D
-
galacto-octopyranoside hydrochloride. 
CAS Number: 7179-49-9 
The structure of lincomycin hydrochloride is: 

ACTIONS 
LINCOCIN (lincomycin hydrochloride) is the monohydrated salt of
lincomycin, a substance 
produced by the growth of a member of the lincolnensis group
of _Streptomyces lincolnensis _
_(fam. Streptomycetaceae)_.  It is a white, or practically white,
crystalline powder and is 
odourless or has a faint odour.  Its solutions are acid and are
dextrorotatory.  LINCOCIN is 
freely soluble in water, soluble in dimethylformamide and very
slightly soluble in acetone. 
LINCOCIN Injection is a clear, colourless or almost colourless
solution, practically free from 
particles. 
MICROBIOLOGY 
_In vitro_ studies indicate that the following organisms are usually
sensitive to concentrations 
achieved normally in the serum following recommended
doses:  _Staphylococcus aureus, _
_Staphylococcus epidermidis_, beta-haemolytic
Streptococcus, _Streptococcus viridans, _
_Streptococcus pneumoniae, Clostridium tetani, Clostridium
perfringens, Corynebacterium _
_diphtheriae._ 

Version: pfdlinci11210 
MoH Approved: 

Commercial/Non-Commercial 
Page 2 of 9 
NOTE: 
The drug is not active against most strains of _Enterococcus
faecalis_, nor against _Neisseria _
_gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae_ or
other gram-negative 
organisms or yeasts.  Some strains of _Clostridium
perfringens_ and strains of some less 
common human pathogens of Clostridia may be lincomycin-resistant.
 Depending on the 
sensitivity of the organism and concentration of the antibiot